时间: 5月20日下午 4:45到8:00
地址: 11120 Roselle St, San Diego, CA 92121，Union Station & Grand Central 会议室
网上报名：http://sabpa.org/html/entresymp/
五月17日前网上报名免费！！

主题1： Presentation #1: Reflections on My 3 year Mission as CEO of Ambit
Ambit Biosciences was founded in 2001, and merged with Daiichi Sankyo in November, 2014. Mr. Martino joined as CEO in November, 2011. As CEO, he guided the company’s development from private to public to the merger, and oversaw the development of the company’s lead asset, quizartinib, from Phase 2a to Phase 3. In his brief talk he will share reflections from his 3 year mission to develop the team, the pipeline and create value for shareholders.
演讲者: Michael A. Martino, Former President & CEO of Ambit Biosciences
Mike Martino was most recently President & CEO of Ambit Biosciences from Nov, 2011 to Jan, 2015, when he departed following the acquisition of Ambit by Daiichi Sankyo. Under his leadership, the Ambit team negotiated an amicable conclusion to a legacy collaborative development agreement with Astellas, concluded a Series E financing, completed the company’s initial public offering, initiated a registrational Phase 3 trial for their lead drug, Quizartinib, and successfully closed the transaction with Daiichi Sankyo in Nov, 2014. Over Mr. Martino’s tenure at Ambit, the team raised nearly $115M in new equity capital, not including the Daiichi Sankyo transaction. Previously, Mr. Martino also worked at Arzeda, a synthetic biology company, and was President & CEO of Sonus Pharmaceuticals, a publicly-traded company located in Bothell, WA.

主题2: Entrepreneurship as a Career Choice for Innovators
In this talk, Dr. Li will tell the story of starting Nexcelom Bioscience, a life science tools company, and share how decisions have been made to start Nexcelom more than 10 years ago, and to develop Nexcelom into a global industry leader in cell counting and analysis, based on innovative image cytometry technologies.

演讲者: Peter Li, President of CEO at Nexcelom Bioscience
Dr. Li is a co-founder and CEO of Nexcelom Bioscience, which develops and markets Cellometer® brand image-based cell counters and analysis systems and Celigo® Adherent Cell Cytometers for the life science market. Under Dr. Li’s leadership, Nexcelom Bioscience was honored as an Inc 500 Company in 2009, as one of fastest growing private companies in America by Inc Magazine. Headquartered in the Boston area, Nexcelom Bioscience now serves pharmaceutical and biotechnology companies, and academic researchers, through its world-wide sites in Bethesda, San Diego, Manchester (UK) and Shanghai (China).

Schedule:
4:45 to 6:00 pm: Reception and Networking
6:00 to 6:10 pm: Welcome and Announcements
6:10 to 7:00 pm: Presentation #1 and Q&A
7:00 to 7:45 pm: Presentation #2 and Q&A
7:45 to 8:00 pm: Networking